{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:48Z","timestamp":1786118868565,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.suc.2026.03.010","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:18:29Z","timestamp":1779103109000},"page":"571-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Genetics in Malignant Melanoma"],"prefix":"10.1016","volume":"106","author":[{"given":"Shannon M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Paul","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.suc.2026.03.010_bib1","first-page":"71","article-title":"Melanoma susceptibility: an update on genetic and epigenetic findings","volume":"12","author":"Truderung","year":"2021","journal-title":"Int J Mol Epidemiol Genet"},{"issue":"4","key":"10.1016\/j.suc.2026.03.010_bib2","doi-asserted-by":"crossref","first-page":"100525","DOI":"10.1016\/j.esmoop.2022.100525","article-title":"Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup","volume":"7","author":"Bruno","year":"2022","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.suc.2026.03.010_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cup.13689","article-title":"Germline mutations predisposing to melanoma","volume":"47","author":"Toussi","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"2","key":"10.1016\/j.suc.2026.03.010_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2023.11.070","article-title":"Germline cancer susceptibility in individuals with melanoma","volume":"91","author":"Funchain","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.suc.2026.03.010_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14373","article-title":"Multiple outcomes of the germline p16INK4a mutation affecting senescence and immunity in human skin","volume":"24","author":"Subramanian","year":"2025","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.suc.2026.03.010_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10555-017-9661-5","article-title":"Identification, genetic testing, and management of hereditary melanoma","volume":"36","author":"Leachman","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"20","key":"10.1016\/j.suc.2026.03.010_bib7","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.suc.2026.03.010_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.suc.2026.03.010_bib9","article-title":"Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations","volume":"5","author":"Wang","year":"2024","journal-title":"Innovation"},{"issue":"1","key":"10.1016\/j.suc.2026.03.010_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s12885-016-2951-4","article-title":"Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?","volume":"16","author":"Schirosi","year":"2016","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.suc.2026.03.010_bib11","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.suc.2026.03.010_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103090","article-title":"Insights into RAS-driven melanoma and its therapeutic implications","volume":"143","author":"Chatziioannou","year":"2026","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.suc.2026.03.010_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2326-6066.CIR-25-0744","article-title":"RAS(ON) multiselective inhibition drives antitumor immunity in preclinical models of NRAS-mutant melanoma","volume":"14","author":"Anastacio Da Costa Carvalho","year":"2026","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"10.1016\/j.suc.2026.03.010_bib14","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.3390\/cancers17223644","article-title":"KIT-mutant melanoma: understanding the pathway to personalized therapy","volume":"17","author":"Kaveti","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.suc.2026.03.010_bib15","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.3390\/jcm14227906","article-title":"Pathway-specific therapeutic modulation of melanoma: Small-molecule inhibition of BRAF-MEK and KIT signaling in contemporary precision oncology with a special focus on vemurafenib, trametinib, and imatinib","volume":"14","author":"Kawczak","year":"2025","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.suc.2026.03.010_bib16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11912-023-01453-x","article-title":"Mucosal melanoma: epidemiology, clinical features, and treatment","volume":"25","author":"Sergi","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.suc.2026.03.010_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74956-3","article-title":"Pathogenic germline variants are associated with poor survival in stage III\/IV melanoma patients","volume":"10","author":"Aoude","year":"2020","journal-title":"Sci Rep"},{"issue":"16","key":"10.1016\/j.suc.2026.03.010_bib18","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.3390\/jcm10163760","article-title":"Familial melanoma and susceptibility genes: a review of the most common clinical and dermoscopic phenotypic aspect, associated malignancies and practical tips for management","volume":"10","author":"Zocchi","year":"2021","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.suc.2026.03.010_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw135","article-title":"Germline CDKN2A mutation status and survival in familial melanoma cases","volume":"108","author":"Helgadottir","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.suc.2026.03.010_bib20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaoncol.2023.0806","article-title":"Risk of syndrome-associated cancers among first-degree relatives of patients with pancreatic ductal adenocarcinoma with pathogenic or likely pathogenic germline variants","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.suc.2026.03.010_bib21","article-title":"Unveiling the genetic landscape of hereditary melanoma: from susceptibility to surveillance","volume":"40","author":"Zheng","year":"2024","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"10.1016\/j.suc.2026.03.010_bib22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamadermatol.2023.2621","article-title":"Estimated prevalence, tumor spectrum, and neurofibromatosis type 1-like phenotype of CDKN2A-Related melanoma-astrocytoma syndrome","volume":"159","author":"Sargen","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.suc.2026.03.010_bib23","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jaad.2020.03.100","article-title":"Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain","volume":"83","author":"Sargen","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"10.1016\/j.suc.2026.03.010_bib24","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.3390\/ijms26136140","article-title":"Skin signals: exploring the intersection of cancer predisposition syndromes and dermatological manifestations","volume":"26","author":"Ochoa-Mellado","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.suc.2026.03.010_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189267","article-title":"An overview of BAP1 biological functions and current therapeutics","volume":"1880","author":"Elsayed","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"10.1016\/j.suc.2026.03.010_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10689-015-9841-9","article-title":"Germline TERT promoter mutations are rare in familial melanoma","volume":"15","author":"Harland","year":"2016","journal-title":"Fam Cancer"},{"key":"10.1016\/j.suc.2026.03.010_bib27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2340\/1651-226X.2025.44048","article-title":"POT1 genetic testing in melanoma-prone families in Sweden: germline variant prevalence and tumor spectrum in identified carriers","volume":"64","author":"Papadakis","year":"2025","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.010_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjd.17443","article-title":"POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families","volume":"181","author":"Potrony","year":"2019","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.suc.2026.03.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100937","article-title":"Characterization of POT1 tumor predisposition syndrome: tumor prevalence in a clinically diverse hereditary cancer cohort","volume":"25","author":"Herrera-Mullar","year":"2023","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.suc.2026.03.010_bib30","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1111\/jdv.19461","article-title":"High- and intermediate-risk susceptibility variants in melanoma families from the mediterranean area: a multicentre cohort from the MelaNostrum consortium","volume":"37","author":"Pellegrini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.suc.2026.03.010_bib31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/jmg-2025-110638","article-title":"UK clinical practice guidelines for the management of patients with constitutional POT1 pathogenic variants","volume":"62","author":"Tsoulaki","year":"2025","journal-title":"J Med Genet"},{"issue":"6","key":"10.1016\/j.suc.2026.03.010_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/diseases13060180","article-title":"Germline Non-CDKN2A variants in melanoma and associated hereditary cancer syndromes","volume":"13","author":"Fiasconaro","year":"2025","journal-title":"Diseases"},{"key":"10.1016\/j.suc.2026.03.010_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14928","article-title":"Structural and functional analysis of the human POT1-TPP1 telomeric complex","volume":"8","author":"Rice","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.suc.2026.03.010_bib34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/cancers12041007","article-title":"Insights into genetic susceptibility to melanoma by gene panel testing: potential pathogenic variants in ACD, ATM, BAP1, and POT1","volume":"12","author":"Pastorino","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.suc.2026.03.010_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdin.2023.01.013","article-title":"Association of germline variants in telomere maintenance genes (POT1, TERF2IP, ACD,and TERT) with spitzoid morphology in familial melanoma: a multi-center case series","volume":"11","author":"Goldstein","year":"2023","journal-title":"JAAD Int"},{"issue":"11","key":"10.1016\/j.suc.2026.03.010_bib36","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41436-021-01240-8","article-title":"Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia","volume":"23","author":"Dalmasso","year":"2021","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.suc.2026.03.010_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev Res"},{"issue":"24","key":"10.1016\/j.suc.2026.03.010_bib38","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1093\/hmg\/ddx368","article-title":"Rare germline variants in known melanoma susceptibility genes in familial melanoma","volume":"26","author":"Goldstein","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.suc.2026.03.010_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","article-title":"Clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients","volume":"22","author":"LaDuca","year":"2020","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.suc.2026.03.010_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/ijms26010023","article-title":"Novel FANCI and RAD54B variants and the observed clinical outcomes in a Hungarian melanoma cohort","volume":"26","author":"Bokor","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.suc.2026.03.010_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/genes14020277","article-title":"Molecular genetic characteristics of FANCI, a proposed new ovarian cancer predisposing gene","volume":"14","author":"Fierheller","year":"2023","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.suc.2026.03.010_bib43","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/1055-9965.EPI-20-1521","article-title":"The impact of longitudinal surveillance on tumor thickness for melanoma-prone families with and without pathogenic germline variants of CDKN2A and CDK4","volume":"30","author":"Sargen","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.suc.2026.03.010_bib44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/jdv.18589","article-title":"Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers","volume":"37","author":"Pissa","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.suc.2026.03.010_bib45","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamadermatol.2017.2926","article-title":"Improvement of genetic testing for cutaneous melanoma in countries with low to moderate incidence: the rule of 2 vs the rule of 3","volume":"153","author":"Delaunay","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.suc.2026.03.010_bib46","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/ced\/llae221","article-title":"Retrospective study of germline variants in patients with hereditary melanoma study criteria in a real clinical practice setting","volume":"49","author":"Villa-Gonzalez","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.010_bib47","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamadermatol.2022.0489","article-title":"Dermatopathologist perceptions of overdiagnosis of melanocytic skin lesions and association with diagnostic behaviors","volume":"158","author":"Kerr","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.suc.2026.03.010_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/jmedgenet-2020-107251","article-title":"Association between a 46-SNP polygenic risk score and melanoma risk in Dutch patients with familial melanoma","volume":"58","author":"Potjer","year":"2021","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.suc.2026.03.010_bib49","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/biology13110954","article-title":"Polygenic risk score improves melanoma risk assessment in a patient cohort from the Veneto region of Italy","volume":"13","author":"Pellegrini","year":"2024","journal-title":"Biology"},{"issue":"12","key":"10.1016\/j.suc.2026.03.010_bib50","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.jid.2018.05.023","article-title":"Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies","volume":"138","author":"Cust","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.suc.2026.03.010_bib51","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41588-020-0611-8","article-title":"Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility","volume":"52","author":"Landi","year":"2020","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.suc.2026.03.010_bib52","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/ijms26104674","article-title":"Polygenic risk score analysis of 37 SNPs associated with melanoma risk in Colombian population","volume":"26","author":"Tovar-Parra","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.suc.2026.03.010_bib53","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/bjd.20956","article-title":"Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts","volume":"186","author":"Steinberg","year":"2022","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.suc.2026.03.010_bib54","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jnci\/djab076","article-title":"Genomic risk score for melanoma in a prospective study of older individuals","volume":"113","author":"Bakshi","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.suc.2026.03.010_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10689-024-00401-3","article-title":"Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant","volume":"23","author":"Onnekink","year":"2024","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.suc.2026.03.010_bib56","article-title":"Psychological distress and quality of life in families with a germline CDKN2A pathogenic variant","volume":"13","author":"Onnekink","year":"2025","journal-title":"Mol Genet Genom Med"},{"issue":"6","key":"10.1016\/j.suc.2026.03.010_bib57","article-title":"Screening for reducing morbidity and mortality in malignant melanoma","volume":"6","author":"Johansson","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.suc.2026.03.010_bib58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","article-title":"Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients","volume":"83","author":"Greenhaw","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.suc.2026.03.010_bib59","article-title":"Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-Gene expression profile for cutaneous melanoma","volume":"5","author":"Hsueh","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.suc.2026.03.010_bib60","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1245\/s10434-024-16379-2","article-title":"Society of surgical oncology gene expression profiling consensus statement work group. Society of surgical oncology consensus statement: assessing the evidence for and utility of gene expression profiling of primary cutaneous melanoma","volume":"32","author":"Bartlett","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.suc.2026.03.010_bib61","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/1878-0261.70020","article-title":"Germline variants in CDKN2A wild-type melanoma prone families","volume":"19","author":"Iversen","year":"2025","journal-title":"Mol Oncol"},{"issue":"9","key":"10.1016\/j.suc.2026.03.010_bib62","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamadermatol.2024.2601","article-title":"Exploring the germline genetics of in situ and invasive cutaneous melanoma: a genome-wide association study meta-analysis","volume":"160","author":"Ingold","year":"2024","journal-title":"JAMA Dermatol"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:58:02Z","timestamp":1786035482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610926000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0039610926000381"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.010","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Genetics in Malignant Melanoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}